Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | BCL2 | P10415 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.31 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.31 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.31 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12938268 | 0.87 | HDAC8 (0.36) | HTTHDAC8HSP90AA1MAPTAHR | |
| SCHEMBL29727517 | 0.80 | LMNA (0.52) | HTTLMNAHDAC8MAPTABCC9 | |
| SCHEMBL871319 | 0.80 | LMNA (0.52) | HTTLMNAHDAC8MAPTABCC9 | |
| SCHEMBL27684655 | 0.75 | LMNA (0.48) | HTTLMNAHDAC8MAPTABCC9 | |
| SCHEMBL10845930 | 0.73 | ALDH1A1 (0.44) | HTTLMNAHDAC8MAPTAHR | |
| SCHEMBL27882709 | 0.73 | — | — | |
| SCHEMBL308765 | 0.73 | KDM4E (0.42) | HTTLMNAHSP90AA1MAPTKDM4E | |
| SCHEMBL1367623 | 0.72 | CYP1A2 (0.38) | HTTLMNAMAPTBCL2CYP2A6 | |
| SCHEMBL308655 | 0.71 | TSHR (0.44) | LMNAHSP90AA1MAPTMEN1KMT2A | |
| SCHEMBL16125565 | 0.68 | SPR (0.35) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10219730-B2 | Redox polymers | ABBOTT DIABETES CARE INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20160296147-A1 | Redox Polymers | THERASENSE, INC. | 2016-10-13 | — | — | US | disclosed |
| US-9320467-B2 | Redox polymers | ABBOTT DIABETES CARE INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20140364710-A1 | Redox Polymers | THERASENSE, INC. | 2014-12-11 | — | — | US | disclosed |
| US-8828204-B2 | Redox polymers | ABBOTT DIABETES CARE INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8795490-B2 | Redox polymers | ABBOTT DIABETES CARE INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8512534-B2 | Redox polymers | ABBOTT DIABETES CARE INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8168052-B2 | Transition metal complexes with bidentate ligand having an imidazole ring | ABBOTT DIABETES CARE INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8092662-B2 | Redox polymers | ABBOTT DIABETES CARE INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20110303538-A1 | Redox Polymers | ABBOTT DIABETES CARE INC. | 2011-12-15 | — | — | US | disclosed |
| US-20110303537-A1 | Redox Polymers | ABBOTT DIABETES CARE INC. | 2011-12-15 | — | — | US | disclosed |
| US-20110306111-A1 | Redox Polymers | ABBOTT DIABETES CARE INC. | 2011-12-15 | — | — | US | disclosed |
| US-20100288634-A1 | Transition Metal Complexes with Bidentate Ligand Having an Imidazole Ring | ABBOTT DIABETES CARE INC. | 2010-11-18 | — | — | US | disclosed |
| EP-1230248-B1 | TRANSITION METAL COMPLEXES ATTACHED TO A POLYMER VIA A FLEXIBLE CHAIN | THERASENSE INC (US) | 2007-06-06 | — | — | EP | disclosed |
| US-6605200-B1 | Charge transfer compounds comprising polymers such as polyvinylpyridine and/or copolymers coupled to osmium compounds, used as biosensors in redox systems | THERASENSE, INC. | 2003-08-12 | — | — | US | disclosed |
| EP-1230248-A2 | TRANSITION METAL COMPLEXES ATTACHED TO A POLYMER VIA A FLEXIBLE CHAIN | Therasense, Inc. (US) | 2002-08-14 | — | — | EP | disclosed |
| WO-2001036660-A2 | TRANSITION METAL COMPLEXES ATTACHED TO A POLYMER VIA A FLEXIBLE CHAIN | THERASENSE, INC. (US) | 2001-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10219730-B2 | Redox polymers | PPOX, OTC, ME3 | HTT 4796/4885LMNA 4829/4885HDAC8 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.